Uploaded August 2025 | Updated September 2026, 17 hours ago
Cancer cells have evolved ways to hide from the immune system. This video explains how Targeron Therapeutics is tackling one of the most universal immune evasion strategies.
Discover how our innovative approach could transform immunotherapy and open new possibilities for treating multiple tumor types.
In this explainer video, we introduce Targeron Therapeutics’ groundbreaking technology, which targets the chronic exposure of Phosphatidylserine (PS) on tumor cell surfaces, a mechanism that suppresses immune responses and promotes cancer growth. By combining PS-targeting molecules with two types of Interferons, this therapy reactivates suppressed immune cells and strengthens the body’s natural ability to destroy cancer cells.
Unlike traditional immunotherapies like Checkpoint Inhibitors, which help only a subset of patients, this approach addresses an ancient and widespread cancer defense, offering the potential to benefit a broader range of patients. The project unites experts in immunology, oncology, and advanced therapeutic development to advance a new era of cancer treatment.
Learn more: targeron.com
#Immunotherapy #CancerResearch #Oncology #Phosphatidylserine #CheckpointInhibitors #CART #CancerTreatment #TargeronTherapeutics #ExplainerVideo #BiotechInnovation
Cancer cells have evolved ways to hide from the immune system. This video explains how Targeron Therapeutics is tackling one of the most universal immune evasion strategies.
Discover how our innovative approach could transform immunotherapy and open new possibilities for treating multiple tumor types.
In this explainer video, we introduce Targeron Therapeutics’ groundbreaking technology, which targets the chronic exposure of Phosphatidylserine (PS) on tumor cell surfaces, a mechanism that suppresses immune responses and promotes cancer growth. By combining PS-targeting molecules with two types of Interferons, this therapy reactivates suppressed immune cells and strengthens the body’s natural ability to destroy cancer cells.
Unlike traditional immunotherapies like Checkpoint Inhibitors, which help only a subset of patients, this approach addresses an ancient and widespread cancer defense, offering the potential to benefit a broader range of patients. The project unites experts in immunology, oncology, and advanced therapeutic development to advance a new era of cancer treatment.
Learn more: targeron.com
#Immunotherapy #CancerResearch #Oncology #Phosphatidylserine #CheckpointInhibitors #CART #CancerTreatment #TargeronTherapeutics #ExplainerVideo #BiotechInnovation










